ArticleDrug and alcohol dependence2020
Buprenorphine prescription dispensing rates and characteristics following federal changes in prescribing policy, 2017-2018: A cross-sectional study.
Article in Drug and alcohol dependence, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 47 citations in OpenAlex.
- Implementation Outcomes of Low Threshold Care for Persons with Opioid Use Disorders.Journal of general internal medicine · 2026Article
- Patient Profiles of Buprenorphine Initiators in General Healthcare Settings: A Latent Class Approach.Journal of general internal medicine · 2026Article
- Pharmacists' Knowledge and Perceptions of Buprenorphine at New York State Pharmacies: Identifying the Extent of Pharmacy-Level Barriers to Access Buprenorphine.Clinical therapeutics · 2025Article
- Three trajectories of implementation of medications for opioid use disorder in primary care.Addiction science & clinical practice · 2025Article
- Assessing buprenorphine treatment utilization and SAMHSA DATA waiver provider distribution in 2021: a real-world analysis in California.Scientific reports · 2025Article
- Medication for Opioid Use Disorder in Federally Qualified Health Centers.JAMA network open · 2025Article
- Federal Impacts on Buprenorphine Prescribing in Washington State, 2012 to 2022.American journal of public health · 2024Article
- Preventable Premature Deaths from the Five Leading Causes of Death in Nonmetropolitan and Metropolitan Counties, United States, 2010-2022.Morbidity and mortality weekly report. Surveillance summaries (Washington, D.C. : 2002) · 2024Article
- Real-World Dispensing of Buprenorphine in California during Prepandemic and Pandemic Periods.Healthcare (Basel, Switzerland) · 2024Article
- Racial/ethnic disparities in timely receipt of buprenorphine among Medicare disability beneficiaries.Drug and alcohol dependence · 2023Article
- Nurse prescribing practices across the globe for medication-assisted treatment of the opioid use disorder (MOUD): a scoping review.Harm reduction journal · 2023Article
- Opioid Use Disorder Practice by Licensure Category in North Carolina.North Carolina medical journal · 2023Article
- Buprenorphine Utilization and Prescribing Among New Jersey Medicaid Beneficiaries After Adoption of Initiatives Designed to Improve Treatment Access.JAMA network open · 2023Article
- Building medication for opioid use disorder prescriber capacity during the opioid epidemic: Prescriber recruitment trends and methods.Journal of substance use and addiction treatment · 2023Article
- Buprenorphine Dispensing Among Youth Aged ≤19 Years in the United States: 2015-2020.Pediatrics · 2023Article
- Characterization of Unintentional Deaths Among Buprenorphine Users.Journal of studies on alcohol and drugs · 2023Article
- Perceptions of buprenorphine barriers and efficacy among nurse practitioners and physician assistants.Addiction science & clinical practice · 2022Article
- The Association Between Scope of Practice Regulations and Nurse Practitioner Prescribing of Buprenorphine After the 2016 Opioid Bill.Medical care research and review : MCRR · 2022Article
- The effect of Medicaid expansion on state-level utilization of buprenorphine for opioid use disorder in the United States.Drug and alcohol dependence · 2022Article
- The impact of CARA mandates on nurse practitioner controlled substance prescribing in Oregon: a cohort study.Substance abuse treatment, prevention, and policy · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
backgroundExpansion of buprenorphine for opioid use disorder treatment is a core component of the opioid overdose epidemic response. The Comprehensive Addiction and Recovery Act (CARA) of 2016 authorized nurse practitioners (NPs) and physician assistants (PAs) to obtain a DATA-waiver to prescribe buprenorphine. The objectives of this study are to examine national- and county-level buprenorphine prescription dispensing, patterns by patient demographics and clinician specialty, and county-level characteristics associated with buprenorphine dispensing.
methodsRetrospective analysis of buprenorphine prescriptions dispensed from approximately 92% of all retail prescriptions in the US (2017-2018). Analyses include rates of buprenorphine prescriptions dispensed, by patient demographics and prescriber specialty, changes in buprenorphine prescriptions dispensed at the national- and county-level, and county-level characteristics associated with buprenorphine dispensing.
resultsBuprenorphine prescriptions dispensed increased by 9.1% nationally, from 40.7-44.4 per 1000 residents. From 2017 to 2018, NPs (351.9%) and PAs (257.3%) had the largest percent increases in dispensed buprenorphine prescriptions, accounting for 79.6% of the total increase. In 2018, county-level characteristics associated with high buprenorphine dispensing included. among others: greater potential buprenorphine treatment capacity, higher drug overdose death rates, and higher rates of Medicaid enrollment. Rural counties were associated with low buprenorphine dispensing.
conclusionBuprenorphine dispensing rates increased in the US from 2017 to 2018, suggesting the addition of NPs and PAs by CARA has contributed to an increase in dispensed buprenorphine prescriptions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.